Reversing Drug Resistance in Tumors with Clickable Antibody Pairs

利用可点击的抗体对逆转肿瘤的耐药性

基本信息

  • 批准号:
    10566266
  • 负责人:
  • 金额:
    $ 63.38万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-01-01 至 2027-12-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY/ABSTRACT – The incidence of gastric and breast cancers is increasing rapidly, rating fourth and fifth leading causes of cancer mortality worldwide. In patients clinically classified as HER2-positive (ERBB2 amplification and/or 2+/3+ protein overexpression by immunohistochemistry), antibody-drug conjugates (ADC) prolong progression-free and overall survival. However, these therapies have low activity in HER2-low cancer cells, and not all HER2-positive tumors benefit, or even those who initially respond inevitably develop resistance over time. Guided by preclinical data we obtained in HER2 heterogeneous patient-derived xenografts demonstrating that an increase in HER-ADC endocytosis enhances therapeutic efficacy, we developed approaches of antibody delivery that result in a 15.5-fold increase of ADC internalization in cancer cells. Our novel approach uses pertuzumab and trastuzumab-drug antibodies that click at the surface of cancer cells upon binding distinct HER2 domains to increase the number of HER2-ADC complexes and further enhance the rate of HER2-ADC endocytosis. Antibody-PET imaging studies that we have generated demonstrate that our approach increases the uptake of 89Zr-ADC in heterogeneous tumors containing HER2-high and HER2-low cancer cells. Here, we will optimize clickable pairs of two epitope-distinct antibody-ADC biomolecules to enhance tumor targeting and drug delivery in resistant models of breast and gastric cancer. In addition to test the potential of our approach in cancer cell lines and organoids, we will perform randomized imaging and therapeutic studies in patient-derived breast and gastric xenografts representing three tumor populations: ADC-eligible tumors of HER2 heterogeneity, ADC-ineligible tumors, and ADC-resistant tumors. We will determine the molecular imaging (89Zr-Antibody PET), safety, pharmacokinetic profile, and therapeutic efficacy of ADC alone (no-click) versus ADC plus pertuzumab conjugated with clicking pairs (click). These randomized preclinical studies will allow us to identify molecular features that confer drug sensitivity or resistance to this promising investigational approach. Aim 1 will optimize pertuzumab/ADC clicking pairs with improved tumor uptake and drug delivery when compared with ADC monotherapies and Aim 2 will validate the use of antibody clicking pairs as a new therapeutic approach. The two aims will provide important new preclinical data on the use of antibody clicking pairs to enhance drug delivery, which could provide an excellent foundation for many future investigations, including the clinical translation of using clicking pairs to enhance drug delivery and the potential broader application to other membrane receptors and heterogeneous tumors. The long-term translational objectives of the studies proposed are to establish a foundation for a clinical trial using antibody clicking to prevent or delay drug resistance in patients with heterogeneous breast and gastric cancers.
项目总结/摘要-胃癌和乳腺癌的发病率正在迅速增加, 第四和第五大癌症死亡原因。临床分类为HER 2阳性的患者 (ERBB 2扩增和/或2+/3+蛋白过表达,免疫组织化学法),抗体-药物偶联物 (ADC)延长无进展生存期和总生存期。然而,这些疗法在HER 2-低表达中具有低活性。 癌细胞,并不是所有的HER 2阳性肿瘤受益,甚至那些最初反应不可避免地发展 时间的阻力。根据我们在HER 2异质性患者来源的异种移植物中获得的临床前数据, 证明HER-ADC内吞作用的增加增强了治疗效果,我们开发了 抗体递送方法导致癌细胞中ADC内化增加15.5倍。我们 一种新的方法使用帕妥珠单抗和曲妥珠单抗药物抗体, 结合不同的HER 2结构域,以增加HER 2-ADC复合物的数量,并进一步提高HER 2-ADC复合物的速率。 HER 2-ADC内吞作用。我们已经产生的抗体PET成像研究表明,我们的 一种方法增加了含有HER 2高和HER 2低的异质性肿瘤中89 Zr-ADC的摄取 癌细胞在这里,我们将优化两个表位不同的抗体-ADC生物分子的可点击对,以增强 乳腺癌和胃癌耐药模型中的肿瘤靶向和药物递送。除了测试潜在的 我们的方法在癌细胞系和类器官,我们将进行随机成像和治疗研究 在代表三种肿瘤群体的患者来源的乳腺和胃异种移植物中: HER 2异质性、ADC不合格肿瘤和ADC耐药肿瘤。我们将通过分子成像 (89 Zr-抗体PET)、安全性、药代动力学特征和单独ADC(无点击)与 与点击对缀合的ADC加帕妥珠单抗(点击)。这些随机临床前研究将使我们 以确定分子特征,赋予药物敏感性或耐药性,这一有前途的研究方法。 目标1将优化帕妥珠单抗/ADC点击对,与对照相比, 与ADC单一疗法和Aim 2将验证抗体点击对作为一种新的治疗方法的使用。 这两个目标将为使用抗体点击对增强药物治疗提供重要的新临床前数据。 交付,这可以为许多未来的研究提供良好的基础,包括临床 使用点击对来增强药物递送的翻译以及对其他药物递送的潜在更广泛应用。 膜受体和异质性肿瘤。拟议研究的长期转化目标 是为利用抗体点击来预防或延缓耐药性的临床试验奠定基础, 异质性乳腺癌和胃癌患者。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Patricia Manuela Ribeiro Pereira其他文献

Patricia Manuela Ribeiro Pereira的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 63.38万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 63.38万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 63.38万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 63.38万
  • 项目类别:
    Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 63.38万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 63.38万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 63.38万
  • 项目类别:
    Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
  • 批准号:
    10699504
  • 财政年份:
    2023
  • 资助金额:
    $ 63.38万
  • 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
  • 批准号:
    10491642
  • 财政年份:
    2023
  • 资助金额:
    $ 63.38万
  • 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
  • 批准号:
    10782567
  • 财政年份:
    2023
  • 资助金额:
    $ 63.38万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了